OncoCyte: A New Investment Opportunity in Transplant Rejection Testing

Lake Street Capital Markets has recently started coverage of OncoCyte, a diagnostics company that specializes in transplant rejection testing. The investment firm has designated OncoCyte as a ‘buy’, recognizing its substantial potential for growth within this niche area of healthcare.

Potential Growth in Transplant Rejection Testing

OncoCyte is positioning itself to capitalize on the expanding market for transplant rejection testing. This market is critical for improving patient outcomes following organ transplants, as timely and accurate testing can greatly influence patient care. Lake Street's analysts believe that OncoCyte's innovative strategies could lead to significant advancements in this field.

Investment Outlook and Price Target

Lake Street has set a price target of $5 for OncoCyte's shares, which suggests a potential upside of approximately 55% based on the stock's closing price on March 27. This optimistic outlook is backed by the company’s strategic initiatives and the increasing demand for effective transplant monitoring solutions.

OncoCyte, investment, healthcare